Development of a High-Content Screening Assay Panel to Accelerate Mechanism of Action Studies for Oncology Research

Efficient elucidation of the biological mechanism of action of novel compounds remains a major bottleneck in the drug discovery process. To address this need in the area of oncology, we report the development of a multiparametric high-content screening assay panel at the level of single cells to dramatically accelerate understanding the mechanism of action of cell growth–inhibiting compounds on a large scale. Our approach is based on measuring 10 established end points associated with mitochondrial apoptosis, cell cycle disruption, DNA damage, and cellular morphological changes in the same experiment, across three multiparametric assays. The data from all of the measurements taken together are expected to help increase our current understanding of target protein functions, constrain the list of possible targets for compounds identified using phenotypic screens, and identify off-target effects. We have also developed novel data visualization and phenotypic classification approaches for detailed interpretation of individual compound effects and navigation of large collections of multiparametric cellular responses. We expect this general approach to be valuable for drug discovery across multiple therapeutic areas.

[1]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[2]  Albert H Gough,et al.  Early Safety Assessment Using Cellular Systems Biology Yields Insights into Mechanisms of Action , 2010, Journal of biomolecular screening.

[3]  K. Glaser,et al.  Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization , 2010, Proceedings of the National Academy of Sciences.

[4]  Rebecca E. Walls,et al.  High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells , 2010, Molecular Cancer Therapeutics.

[5]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[6]  R. Higgs,et al.  Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool. , 2009, Journal of proteome research.

[7]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[8]  J. Waring,et al.  Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans , 2008, Journal of biomolecular screening.

[9]  S. Haney.  Expanding the repertoire of RNA interference screens for developing new anticancer drug targets , 2007, Expert opinion on therapeutic targets.

[10]  Y. Iwamoto,et al.  Cyclin‐dependent kinase inhibitor, flavopiridol, induces apoptosis and inhibits tumor growth in drug‐resistant osteosarcoma and Ewing's family tumor cells , 2007, International journal of cancer.

[11]  Paolo Cappella,et al.  Multiparametric Cell Cycle Analysis by Automated Microscopy , 2006, Journal of biomolecular screening.

[12]  J. Rice,et al.  The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action. , 2006, Assay and drug development technologies.

[13]  P. Bernardi,et al.  High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening , 2006, Archives of Toxicology.

[14]  R. Marouga,et al.  The development of the DIGE system: 2D fluorescence difference gel analysis technology , 2005, Analytical and bioanalytical chemistry.

[15]  C. Hart,et al.  Finding the target after screening the phenotype. , 2005, Drug discovery today.

[16]  T. Misteli,et al.  Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome , 2005, Nature Medicine.

[17]  K. Glaser,et al.  Differential protein acetylation induced by novel histone deacetylase inhibitors. , 2004, Biochemical and biophysical research communications.

[18]  S. Pastorino,et al.  Induction of Apoptosis by Flavopiridol in Human Neuroblastoma Cells Is Enhanced under Hypoxia and Associated With N-myc Proto-oncogene Down-Regulation , 2004, Clinical Cancer Research.

[19]  Lani F. Wu,et al.  Multidimensional Drug Profiling By Automated Microscopy , 2004, Science.

[20]  T. Garyantes,et al.  Identification of Gap Junction Blockers Using Automated Fluorescence Microscopy Imaging , 2003, Journal of biomolecular screening.

[21]  Douglas C. Miller,et al.  Flavopiridol Induces Mitochondrial-Mediated Apoptosis in Murine Glioma GL261 Cells via Release of Cytochrome c and Apoptosis Inducing Factor , 2003, Cell cycle.

[22]  W. Van den Broeck,et al.  Morphological and Biochemical Aspects of Apoptosis, Oncosis and Necrosis , 2002, Anatomia, histologia, embryologia.

[23]  J. Gardner.  Cellular phenotypes and the genetics of hypertension , 2002, Current hypertension reports.

[24]  Junjie Chen,et al.  Histone H2AX Is Phosphorylated in an ATR-dependent Manner in Response to Replicational Stress* , 2001, The Journal of Biological Chemistry.

[25]  G. Landreth,et al.  β-Amyloid Stimulation of Microglia and Monocytes Results in TNFα-Dependent Expression of Inducible Nitric Oxide Synthase and Neuronal Apoptosis , 2001, The Journal of Neuroscience.

[26]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[27]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[28]  Albert Gough,et al.  High-Content Screening: A New Approach to Easing Key Bottlenecks in the Drug Discovery Process , 1997 .

[29]  A. Edwards,et al.  Synchronisation by hydroxyurea does not affect the sensitivity of CEM-C7 lymphoblasts to glucocorticoids. , 1984, British Journal of Cancer.

[30]  Fuchs Da,et al.  Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. , 1978 .

[31]  Horwitz Sb.  Novel inhibitors of RNA synthesis. , 1974 .

[32]  John A. Tallarico,et al.  Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.

[33]  Cynthia L Adams,et al.  Compound classification using image-based cellular phenotypes. , 2006, Methods in enzymology.

[34]  D. L. Taylor,et al.  High content screening applied to large-scale cell biology. , 2004, Trends in biotechnology.

[35]  J. Lazo,et al.  A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity. , 2004, Oncology research.

[36]  Sudhir Gupta,et al.  Molecular signaling in death receptor and mitochondrial pathways of apoptosis (Review). , 2003, International journal of oncology.

[37]  G. Landreth,et al.  beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  G. Majno,et al.  Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.

[39]  R. Johnson,et al.  Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. , 1978, Cancer treatment reports.

[40]  S. Horwitz.  Novel inhibitors of RNA synthesis. , 1974, Federation proceedings.